Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A mini-review.


Journal

Neuroscience and biobehavioral reviews
ISSN: 1873-7528
Titre abrégé: Neurosci Biobehav Rev
Pays: United States
ID NLM: 7806090

Informations de publication

Date de publication:
10 2022
Historique:
received: 19 06 2022
revised: 01 09 2022
accepted: 02 09 2022
pubmed: 10 9 2022
medline: 28 9 2022
entrez: 9 9 2022
Statut: ppublish

Résumé

Dementia with Lewy bodies (DLB) is a neurodegenerative disease linked to abnormal accumulation of phosphorylated α-synuclein. GBA1 is the gene encoding the lysosomal enzyme glucocerebrosidase (GCase), whose mutations are a risk factor of DLB. To report all available data exploring the association between GBA1 mutations and DLB. All publications focused on GCase and DLB in humans between 2003 and 2022 were identified on PubMed, Cochrane and ClinicalTrials.gov. 29 studies were included and confirmed the strong association between GBA1 mutations and DLB (Odds Ratio [OR]: 8.28). GBA1 mutation carriers presented a more malignant phenotype, with earlier symptom onset, more severe motor and cognitive dysfunctions, more visual hallucinations and rapid eye movement sleep disorder. GBA1 mutations were associated with "purer" neuropathological DLB. No therapeutic recommendations exist and clinical trials targeting GCase are just starting in DLB patients. This review reports a link between GBA1 mutations and the DLB phenotype with limited evidence due to the small number of studies.

Identifiants

pubmed: 36084847
pii: S0149-7634(22)00345-1
doi: 10.1016/j.neubiorev.2022.104856
pii:
doi:

Substances chimiques

alpha-Synuclein 0
Glucosylceramidase EC 3.2.1.45

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104856

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Auteurs

Sinead Gaubert (S)

Université de Paris Cité; Centre de Neurologie Cognitive, GHU AP-HP Nord, Hôpital Lariboisière Fernand-Widal, Paris, France; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris Cité, France.

Claire Hourregue (C)

Centre de Neurologie Cognitive, GHU AP-HP Nord, Hôpital Lariboisière Fernand-Widal, Paris, France.

François Mouton-Liger (F)

Université de Paris Cité; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris Cité, France.

Périne Millot (P)

Université de Paris Cité; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris Cité, France.

Mélanie Franco (M)

Université de Paris Cité; UMR-S1134, BIGR, Inserm, Laboratoire d'Excellence GR-Ex, Paris, France.

Elodie Amar-Bouaziz (E)

Université de Paris Cité; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris Cité, France; Département de Biochimie, GHU AP-HP Nord, Hôpital Lariboisière Fernand-Widal, Paris, France.

Dag Aarsland (D)

Department of Old Age Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, UK; Centre for Age-Related Diseases, Stavanger University Hospital, Stavanger, Norway.

Jacques Hugon (J)

Université de Paris Cité; Centre de Neurologie Cognitive, GHU AP-HP Nord, Hôpital Lariboisière Fernand-Widal, Paris, France; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris Cité, France.

Claire Paquet (C)

Université de Paris Cité; Centre de Neurologie Cognitive, GHU AP-HP Nord, Hôpital Lariboisière Fernand-Widal, Paris, France; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris Cité, France. Electronic address: claire.paquet@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH